Acute renal failure and Fanconi syndrome due to deferasirox.
Deferasirox is the first oral iron chelator and, as such, is widely used for the treatment of chronic iron overload. However, recent data from large studies confirmed the renal toxicity of deferasirox. We report a case of Fanconi syndrome associated with acute renal failure in a patient receiving deferasirox. In particular, new insights regarding the pathophysiology of the renal disease due to this treatment are discussed. This case highlights the importance of a careful monitoring of kidney function, markers of proximal tubulopathy and ferritinaemia in patients receiving deferasirox.
Grangé
Steven
S
Nephrology Department, Rouen University Hospital, 1 Avenue de Germont, 76031 Rouen Cedex, Rouen, France. stevengrange@gmail.com
Bertrand
Dominique M
DM
Guerrot
Dominique
D
Eas
Florence
F
Godin
Michel
M
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D000368:Aged; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D002908:Chronic Disease; D000077588:Deferasirox; D005198:Fanconi Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy; D007668:Kidney / Q000503:physiopathology; D008297:Male; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox